TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07638566: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculon

Sponsor: argenx · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,053,064

Rescue Site Savings

+$4,638,928

Unlock Full NCT07638566 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07638566 Rescue Dossier →